Treatment of Influenza A
Start antiviral treatment immediately with oseltamivir (oral), zanamivir (inhaled), or peramivir (IV) as a single neuraminidase inhibitor—do not delay for test results if you have high clinical suspicion, and treat for 5 days in uncomplicated cases 1.
Who Must Receive Antiviral Treatment
You should start antivirals as soon as possible for:
- Any hospitalized patient with influenza, regardless of how long they've been sick 1
- Any patient with severe or progressive illness, regardless of duration 1
- High-risk outpatients, including:
For otherwise healthy outpatients not at high risk, you can consider treatment but it's optional 1.
Which Antiviral to Use
Use a single neuraminidase inhibitor—never combine them 1:
- Oseltamivir (oral): First-line for most patients, especially severe cases 1, 2
- Zanamivir (inhaled): Alternative option
- Peramivir (IV): Single-dose option or for patients who cannot take oral/inhaled medications
The 2024 WHO guidelines add nuance: baloxavir is conditionally recommended for high-risk non-severe cases within 48 hours of symptom onset, while oseltamivir remains the choice for severe cases 2, 3. However, the IDSA guidelines (which are U.S.-focused) don't differentiate between antivirals for different severity levels and recommend any neuraminidase inhibitor 1.
Treatment Duration
- 5 days for uncomplicated influenza in healthy ambulatory patients 1
- Consider longer duration for immunocompromised patients or those hospitalized with severe lower respiratory disease (pneumonia, ARDS), as viral replication is often prolonged 1
Critical Pitfalls to Avoid
Do NOT wait for test confirmation to start treatment in high-risk or severely ill patients—begin empirically based on clinical suspicion 1.
Do NOT use higher than FDA-approved doses of neuraminidase inhibitors routinely 1.
Do NOT give corticosteroids for influenza treatment unless indicated for another reason (e.g., COPD exacerbation, septic shock)—they are associated with harm 1, 2, 4.
Managing Bacterial Coinfection
You must investigate and empirically treat bacterial coinfection in two scenarios:
- Patients presenting initially with severe disease (extensive pneumonia, respiratory failure, hypotension) 1
- Patients who deteriorate after initial improvement, particularly those on antivirals 1
However, do NOT routinely give antibiotics to non-severe influenza patients without evidence of bacterial infection 5, 2. This is a strong recommendation against unnecessary antibiotic use 5.
When Treatment Fails
If patients fail to improve after 3-5 days or deteriorate despite antiviral treatment:
- Investigate bacterial coinfection 1
- Consider other diagnoses besides influenza 1
- Consider resistance testing for immunocompromised patients with persistent viral replication after 7-10 days 1
Diagnostic Testing Strategy
For suspected severe influenza: Use RT-PCR or other molecular assays (NAAT)—they are far more sensitive than rapid tests 1, 3.
For non-severe influenza: Use NAAT or digital immunoassay (DIA) 3.
Do NOT use rapid antigen tests (RIDTs) in hospitalized patients except when molecular assays are unavailable, and confirm negative results with RT-PCR 1.
What NOT to Use
Strong evidence against these interventions:
- Corticosteroids (unless indicated for other reasons) 1, 2, 4
- Macrolide antibiotics (without bacterial coinfection) 2, 3
- mTOR inhibitors 2, 3
- NSAIDs as adjunctive therapy 2
- Intravenous immunoglobulin 1
- Combination neuraminidase inhibitors 1
Real-World Implementation Note
Despite clear guidelines, only 58% of high-risk children receive appropriate antiviral treatment 6. The most common barriers include emergency department settings (where treatment rates are lower) and lack of recognition of high-risk status. Don't fall into this gap—be aggressive about identifying high-risk patients and treating them immediately.